Join to View Full Profile
Duke Medical Ctr# DumcDurham, NC 27710
Phone+1 888-275-3853
Dr. Salama is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2007 - 2010- University of ChicagoResidency, Internal Medicine, 2004 - 2007
University of North Carolina at Chapel Hill School of MedicineClass of 2004
Certifications & Licensure
NC State Medical License 2010 - 2025
IL State Medical License 2004 - 2011
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
- Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
- A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study.Kristen E Rhodin, Margaret H O'Connor, Aaron Therien, Shayna Hollander, Viviana Geron
Annals of Surgical Oncology. 2025-03-27 - Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.Jeffrey Weber, Waqas Haque, Svetomir N Markovic, April K S Salama, Inderjit Mehmi
The Oncologist. 2025-03-10 - Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy.Randol Kennedy, Calvin Rei L Macrohon, Mary Lourdes Grace V David, Meg Lee, April K S Salama
JCEM Case Reports. 2025-03-01
Lectures
- Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.2019 ASCO Annual Meeting - 6/1/2019
- Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
April Salama’s War on Metastatic MelanomaJune 22nd, 2021- More Options for Treating MelanomaSeptember 28th, 2021
- Skin Cancer Not 'Relatively New,' Dates Back More Than 200 Years | Fact CheckAugust 6th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
